glp-1 agonist or antagonist Trends in the Development of Receptor Agonists Design and Evaluation of Peptide

Wang, L., Xu, R., Kaelber, D

[DOI] [PubMed] [Google Scholar] 173.Neeland IJ, Linge J, Birkenfeld AL

The drugs could produce huge benefits for people with obesity but also present a major cost challenge given the large percentage of the population that is eligible for them, the report said

Does retatrutide have worse side effects than Mounjaro

Also, no significant difference was seen between the exenatide and pooled comparator (placebo and insulin) groups (95% CI: -0.98 to 0.96) [152]

Larger companies are more likely to include coverage for drugs like Wegovy or Zepbound in their benefits, especially if theyve adopted wellness initiatives aimed at reducing obesity-related healthcare costs